TNBC disease is hormone receptor-negative and HER2-negative, is associated with a younger age at diagnosis, a higher tumor grade, a more aggressive clinical course, and poorer prognosis than other types of breast cancer, and is not amenable to endocrine therapy or HER2-targeted agents, such as trastuzumab [6–9]. This evidence concerns the gene ERBB2 and breast carcinoma.